Vertex Pharmaceuticals, Inc.

Blueprint Medicines Corporation

Spero Trinem, Inc.

Pliva D.d.

Emanuele Perola

Paul S Charifson

Tiansheng Wang

Anne-Laure Grillot

Francois Maltais

Huai Gao

Upul Keerthi Bandarage

Yusheng Liao

Wenxin Gu

Mark Willem Ledeboer

John P Duffy

Brian Ledford

Joseph M Kennedy

Michael P Clark

Ioana Davies

Luc J Farmer

Dean P Stamos

Steven M Ronkin

Hongbo Deng

Randy Scott Bethiel

David D Deininger

Joseph Drumm

Arnaud Le Tiran

Arnaud LeTiran

Francesco Gerald Salituro

Joseph L Kim

Jason D Brubaker

John J Court

Chao Lin

M Woods Wannamaker

Ursula A Germann

Dylan H Jacobs

Yi Zhou

Min Jiang

Steven Jones

Ann Dak-Yee Kwong

Thomas A Dineen

Randal Byrn

John Patrick Maxwell

Kevin Michael Cottrell

Qing Tang

Douglas Wilson

Michael John Boyd

Hardwin O'Dowd

Chandrasekhar V Miduturu

Natasja Brooijmans

Youssef Laafiret Bennani

Joshua T Close

Jian Jim Wang

Jeffrey O Saunders

Albert Charles Pierce

Robert J Davies

Kevin J Wilson

John Emmerson Campbell

Jingrong Cao

Jon H Come

Govinda Rao Bhisetti

James A Henderson

David Messersmith

Ronald Lee Grey, Jr

Philip N Collier

Michael Paul DeNinno

Sanjay Shivayogi Magavi

Brett D Williams

Christopher Phillip Locher

Joshua Syken

James Daniel Frantz

Meghan Elise Cockerill

Elisabeth Doyle

Michael J Burke

Brian Anthony Goldman

Adrianne Lynn Kolpak

Christopher De Savi

Meredith Suzanne Eno

Elizabeth Jin-Sun Ryu

Manuel A Navia

Neil Bifulco

Patrick Raymond Connelly

Steven Mark Wenglowsky

Ioana Drutu

Trudy Grossman

Raul Eduardo Krauss

Shi-Kai Tian

Jianglin Liang

Salvatore Anthony Marchese

Andrew Magee

Jun Feng

Scott T Moe

Carlos H Faerman

Aysegül Özen

Richard Vargas

Philip D Ramsden

Randal Bym

Yousef Laafiret Bennani

Shi Kai Tian

Tiensheng Wang

Paul J Ala

Janid A Ali

Jacob J Clement

Christopher Faraday

Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting wild type c-kit kinase and for treating disorders and diseases mediated by wild type c-kit kinase in humans or non-humans.

Wild type kit inhibitors

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

MAP4K1 inhibitors

The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

EGFR inhibitors

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

CDK2 inhibitors

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases:  The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Triazoles for the treatment of demyelinating dieases

The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Triazoles for the treatment of Demyelinating Diseases

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

Combination therapy to treat mycobacterium diseases

Growing community of inventors

Brookline, MA, United States of America

Emanuele Perola